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Chagas Disease: Then and Now
One hundred years after Carlos Cha-
gas’ discovery [1] WHO defines Chagas
disease as one of the most important
infectious diseases of poverty. Beyond its
biological determinants (interplays among
the parasite, vector, and human), the
social determinants of Chagas disease are
of utmost importance; poor housing and
working conditions, low salaries, and
malnutrition are directly linked to Chagas
disease in Latin American [2]. This article
highlights the current state on research
and innovation related to control and care
of Chagas disease, as well as the challenges
for the next decade.
Confronting Reality and
Keeping Transmission Control
in Focus
In 2007, Latin America [3] had an
estimated 8 million to 15 million Trypano-
soma cruzi-infected individuals in 15 afflict-
ed countries, with an incidence of vector
transmission greater than 40,000 cases per
year and the congenital transmission rate
higher than 14,000 cases per year. These
numbers reflect approximately 2 million
infected women of fertile age and almost
30 million people at risk in endemic areas.
The prevalence of infected blood in blood
banks is 1.28%, and 1.8 million individuals
have Chagas disease cardiopathy [4], with
several hundred thousand infected people
living in other nations as a result of
migration [5].
Considering the feasibility of Chagas
disease control, several points must be
discussed, namely:
(i) Permanent surveillance for new
outbreaks due to oral transmission;
(ii) Domiciliary invasion by sylvatic
triatomines, due to the complex
parasite behaviour and ecological
contexts;
(iii) Lack of effective treatment, immu-
noprophylaxis, and feasible mark-
ers for disease progression; and
(iv) Continuous circulation of T. cruzi
isolates largely spread in sylvatic
ecotopes across the American con-
tinent, showing that elimination of
human disease transmission has to
be seen in a new context [6] that is
dependent on local transmission
characteristics and prevalence
[4,5].
Epidemiological parameters have
shown that the success of vector control
policies are due to efforts of large inter-
ventions such as those in the Southern
Cone, Andes, Central America, Mexico,
and Amazon, which have largely reduced
the morbidity and transmission of Chagas
disease [3,4]. In Brazil, for example, the
success of vector control reduced the
incidence of new cases from 100,000 in
1980 to less than 500 notified cases per
year from 2001 to 2006 [7]. Uruguay,
Chile, and Brazil received the Pan Amer-
ican Health Organization (PAHO)/World
Health Organization (WHO) certification
for interruption of Triatoma infestans vector
transmission [3]. However, sustainability
depends on control of autochthonous
triatomines by permanent epidemiological
and entomological surveillance, as annual
oscillating frequencies of house infestation
within the same region have been noted,
particularly in some hotspots in the
Argentinean Gran Chaco [8]. Limited
effectiveness of pyrethroid insecticides
outdoors and in peridomiciliar structures,
development of insecticide resistance, and
sylvatic and semi-domestic vectors might
contribute to residual vector foci even after
insecticide spraying [8], implying a risk of
re-emergence of acute Chagas disease.
Additionally, blood bank control still
reveals high frequencies of seropositive
donors and more attention should be
given to the frequency of seropositive
pregnant women and congenital transmis-
sion, when early access to diagnosis and
treatment is crucial and should be man-
datory [6,7]. Together with the success of
the control programs in some countries of
the Southern Cone, progress in other
endemic areas has been uneven. Mainte-
nance of previously successful control
programs as in Venezuela, fighting to
increase economic resources as in Central
America, and strengthening of official
control programs in Mexico and Peru
would be important to extend the success
of southern countries to all endemic areas.
An important issue that has evolved in
current programs was the divorce of vector
control from Chagas disease assistance to
chronic patients [9]. The first is field-based
with routine insecticide spraying and
vector surveillance; the second is hospi-
tal-based in parallel to blood bank screen-
ing, and diagnosis with treatment and
medical care. More integrated Chagas
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would combine vector control with case
detection/treatment and broad social par-
ticipation. This strategy might help over-
come the difficulties and increase cost-
effectiveness of the control program, its
public acceptance, and its long-term
sustainability. It is important to educate
the community for the surveillance of
vector populations, to create more explicit
guidelines for basic health systems, and to
rapidly detect new acute cases in order to
avoid the re-emergence of Chagas disease.
Among the challenges to be addressed in
the next decades is the continuous main-
tenance of epidemiological surveillance,
which is cost/benefit–favourable. Howev-
er, its priority is low, since Chagas disease
afflicts mostly the poor and socially
marginalized populations, with programs
performed by the public sector, implying
political decisions in sometimes unstable
conditions. In this scenario, new actors
emerge: associations of patients in affected
countries and non-governmental organi-
zations (NGOs), such as the Drugs for
Neglected Diseases initiative (DNDi) and
Me ´dicins Sans Frontie `res (MSF). Commu-
nity engagement and motivation as well as
integration of prevention, including edu-
cational strategies, and treatment are huge
compromises that must be made, and a
‘‘task shift’’ must occur to mitigate a
human resource crisis.
A Vaccine for Chagas Disease:
Reality or Fantasy?
Almost 25 years ago it was believed
that a vaccine against T. cruzi would fulfil
the primary requirements of any pro-
posed vaccine, such as primum non nocere
(first, do no harm), inducing sterile
immunity, and being effective against all
strains. However, the autoimmune hy-
pothesis related to Chagas disease patho-
genesis hampered efforts to develop new
chemotherapy and vaccine approaches
against T. cruzi. Later, the demonstration
that parasite persistence was associated
with Chagas disease progression empha-
sized the importance of parasite control in
ameliorating or hampering disease evolu-
tion [10]. Therefore, vaccines and new
antiparasite drugs became realistic pro-
posals. It is still unclear whether a
prophylactic vaccine has a place in the
current epidemiological picture of Chagas
disease control, whether it would be
better as an immunotherapeutic agent to
delay disease progression, or whether it
should be developed for dogs, which may
play a role as domestic and peridomestic
reservoirs [11]. Furthermore, immuno-
therapeutic vaccines may be alternatives
for improving prognosis in chronic pa-
tients. Evidently, with success will come
the economic barriers to produce and
deliver the vaccine, a common feature of
neglected diseases.
Chagas Disease Therapy:
Exploring the Knowledge
Frontier
For more than three decades, only two
drugs have been available for Chagas
disease: nifurtimox and benznidazole
[12]. Although their use in the acute and
early chronic phases of Chagas disease can
reach a 70% cure rate, solid scientific
evidence is still lacking about its use in the
chronic phase. The BENEFIT program, a
multi-centric and non-randomized follow-
up to evaluate the effect of benznidazole in
chronic patients is underway [12]. It is one
among the only five clinical trials for
Chagas disease registered in the Clinical
Trials database (http://www.clinicaltrials.
gov), a clear indication of the negligence of
the pharmaceutical industry. The urgently
needed pediatric formulation for benzni-
dazole has fortunately been undertaken by
a public pharmaceutical company in
Brazil (LAFEPE) and DNDi.
Two main approaches to the develop-
ment of new drugs against Chagas disease
have been used: target-based strategy,
requiring the study of T. cruzi biology to
discover and target a weak link in
metabolism or pathogenesis; and diversity
or phenotypic screens—new uses for
existing drugs [13]. In fact, sequencing
the T. cruzi genome [14] was an important
advance in understanding its biology and
in improving the identification of possible
new drug targets. Re-annotation and
metabolic pathway reconstruction helps
to predict enzymatic functions and char-
acterize some unique enzymes and path-
ways in T. cruzi aiming to recognize new
potential targets. Other approaches have
also advanced the process: ergosterol
biosynthesis inhibitors, potent anti-fungals,
and promising anti-trypanosomatid agents
that are nearing clinical trials for Chagas
disease, such as ravuconazole and posaco-
nazole [15].
Another advance includes the combina-
tion of registered drugs (nifurtimox and
benznidazole) and their combinations with
other trypanocide compounds and/or
other drugs as amiodarone, an anti-
arrhythmic agent that also has anti-T.
cruzi activity, acting synergistically with
posaconazole [16]. Cell therapy in animal
models and in humans have shown
improvement in right ventricular alter-
ations, although their long-term analysis
revealed that the beneficial effects were
not long lasting [17]. A new avenue to be
explored involves the use of immunomod-
ulators alone or in association with
trypanocidal drugs to ameliorate the
chronic effects of T. cruzi infection.
Diagnosis and Treatment
Follow-up: Challenges in
Chagas Disease
Significant progress has been achieved
in diagnosis since the use of xenodiagnosis
and serologic tests to confirm Chagas
disease. However, although reliable serol-
ogy assays are currently available, espe-
cially for chronic cases, cure and adequate
follow-up diagnostic methods remain a
challenge [18]. After benznidazole therapy
of chronic patients, conventional serology
may remain positive for several years
despite repeated negative parasite detec-
tion [18]. New tools are still necessary and
several new tests need to be validated.
The use of PCR to detect minimal
numbers of T. cruzi DNA in the blood
samples has opened new possibilities for
the diagnosis of acute and chronic Chagas
disease and as an adjunct to conventional
serology [19]. Diagnosis in the Amazon
region (Peru, Ecuador, and Brazil) remains
a puzzle and serology requires appropriate
antigens to represent the heterogeneity of
the T. cruzi strains. It is generally agreed
that evidence is lacking that T. cruzi is
more than a single species; although the
geographical distribution of T. cruzi I and
T. cruzi II in humans varies, both induce
disease [20]. Studies with microsatellites
and mtDNA sequence variants produced
evidence for the existence of a third
phylogenetic T. cruzi lineage, named T.
cruzi III [21]. The questions of whether or
not triatomines play a role as ‘‘biological
filters’’ and whether or not the immune
system differentially controls T. cruzi
lineages await further exploration. A new
multiplex assay platform designed to
detect anti-T. cruzi antibodies using re-
combinant antigens and parasite lysate
may be useful to improve sensitivity and
specificity in diagnostic tests [22]. In
addition, the variety and quality of diag-
nostic targets for Chagas disease have
been substantially improved, offering a
useful tool for determining treatment
success or failure [23]. Furthermore, the
recognition of parasite-specific immune
response alterations after benznidazole
treatment during chronic Chagas disease
has raised the possibility of development of
biomarkers indicative of treatment efficacy
and cure [24].
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Done to Care for the Patients?
Chagas heart disease is the leading
cause of infectious myocarditis worldwide,
and is the most serious and frequent
manifestation of chronic Chagas disease,
with 20%–40% of infected individuals
affected 10–30 years after infection. Per-
sistent low-grade parasitism accompanied
by an unbalanced immunological response
seems to be the main pathogenic mecha-
nism that leads to myocardial damage,
together with microvascular dysfunction
and neuronal loss [10]. Currently, patient
management only mitigates the main
symptoms [9]. The establishment of risk
stratification models and algorithms to
guide mortality risk assessment for thera-
peutic decision-making are crucial, as is
evaluation of functional heart impairment
and prognosis to improve quality of life
and survival rates [10,25]. Multidisciplin-
ary teams committed to the care of Chagas
disease patients have shown that a broader
vision of health care might help clinicians
make decisions closer to the daily reality of
the patient and have a positive impact on
treatment adherence and individual qual-
ity of life [9,25]. The consensus on
priorities for Chagas disease indicates the
need for:
(i) Holistic care of the patients beyond
solely conventional therapy;
(ii) Innovation on drugs or combined
therapies that provide a shorter
treatment course with fewer
side effects, and on paediatric
formulations;
(iii) New tools to follow up treatment
efficacy during the chronic phase;
and
(iv) New biomarkers to identify cure
and assist with stratification and
prognosis of risk factors.
Keep Holding On
Crossing the ‘‘valley of death’’ [26]—
the enormous gap between discovery/
basic science and health products and
services—is a current and permanent
challenge. Translational research has be-
come a major agenda issue [27] and is
certainly needed for all diseases including
those poor populations that suffer the
‘‘neglected diseases.’’ Regarding Chagas
disease, recognition of the relevant de-
crease in the number of new acute cases in
most countries due to successful vector
control programs in the last decades is
certainly not sufficient to control the
disease. As shown in Figure 1, current
social and epidemiological scenarios point
to the following needs:
(i) Sustainable and integrated surveil-
lance strategies and identification
of priority areas for immediate
intervention;
(ii) Provision of adequate, universal,
integral, and holistic care to pa-
tients, with access to available and
new therapies;
(iii) Improvement of diagnostic and
prognostic markers for disease
progress, aiming for more rational
interventions;
(iv) Guaranteed access to information,
education, and social organisations
for Chagas disease patients and
their families;
(v) Creation of more organized, inte-
grated, and collaborative networks
between researchers, physicians,
patients, and policy makers.
A forum is urgently needed to address
the challenges of keeping Chagas disease
on the agendas of scientific and funding
agencies. Even a hundred years after,
Carlos Chagas’ thoughts are undoubtedly
valid right now: ‘‘…for Chagas, only
science directed towards the betterment
of humanity was valid (…) Thus he never
Figure 1. Chagas disease control: Hubs, challenges, and opportunities for the next decade.
doi:10.1371/journal.pntd.0000645.g001
www.plosntds.org 3 June 2010 | Volume 4 | Issue 6 | e645forgot that social and economic factors are
responsible—to a very great extent—for
the situations he witnessed. In this way he
was a precursor to what is most noble
about social medicine. In this respect it is
important to remember his words about
the elimination of American trypanosomi-
asis (…), that the construction of decent
housing, compatible with healthy way of
life, was the most necessary element’’ [28].
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